Cases & Deals

Cellectis completes $228 million IPO

Client(s) Cellectis SA

Jones Day represented Cellectis SA, a French biotechnology company that develops novel cancer treatments, in connection with its $228 million initial public offering in the United States and Nasdaq listing. BofA Merrill Lynch, Jefferies, and Piper Jaffray & Co. acted as lead underwriters for the offering.